Bristol-Myers Squibb Company
boothcheck covers Bristol-Myers Squibb Company (BMY) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Eliquis, an anticoagulant, is the single largest revenue line at 30% of sales, and the annual filing reports its U.S. revenues up 6% in 2025 on higher demand with international revenues up 14%, or 9% excluding currency. • Roughly 46% of revenue sits in products the company itself classifies as legacy, which is the concentration behind its own risk heading: ⟦"We depend on several key products for most of our revenues, cash flows and earnings."⟧ • Second-quarter results are scheduled for the mor
Is BMY overvalued? See what's priced in →
2,457 institutional managers reported holding BMY in 13F filings for the quarter ended 2026-03-31. Together they hold about 74% of the company; the top 10 hold 36%. 222 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 39.6M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (3.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BMY has cut its share count 8.5% over the past five years, spending $16.43B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 15 years straight; the current rate is $2.49 a share annually. Cash returned over the past three years: $13.54B in dividends and $4.00B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BMY over the trailing three years: 2023: 3 buys totaling $673k; 2024: 1 buy totaling $100k; 2025: 3 buys totaling $412k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BMY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-28 | -3.1% | -5.5% |
| 2023-10-27 | -9.9% | +0.6% |
| 2024-02-14 | +0.1% | -2.1% |
| 2024-04-26 | -8.2% | -7.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BMY's latest 8-K filings: 2026-07-30 (items 2.02, 7.01, 9.01); 2026-05-08 (items 5.07); 2026-04-30 (items 2.02, 7.01, 9.01); 2026-02-05 (items 2.02, 7.01, 9.01); 2026-01-12 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.